Background {#Sec1}
==========

Primary melanocytic neoplasms of the central nervous system (CNS) belong to the tumors of the meninges. The incidence is less than 0.1%. Some may relate to certain neurocutaneous syndrome. The tumor can affect the entire CNS, with miscellaneous performances. The diagnosis is always difficult before the pathology result is available. And due to the potential of malignant transformation and dissemination, the identification of the original loci is even harder. So the clinical diagnosis and treatment must base on an overall evaluation of a patient. Primary amelanotic melanoma is a special subtype of the melanocytic neoplasm, which is especially rare. We want to share our experiences of primary CNS melanocytic neoplasms and amelanotic melanoma through our cases with review of the literature.

Case presentation {#Sec2}
=================

Medical history {#Sec3}
---------------

A 64-year-old man presented to our department in December 2013 for progressive right frontal mass with dull aching for 9 months. His medical history was unremarkable except for 2 years of hypertension. The familial history was negative, with no neurocutaneous system disorders of the first grade relatives.

Clinical examination {#Sec4}
--------------------

The vital signs were stable. A mass at the right frontal region could be palpated, about 5 cm in diameter, hard, fixed, with no obviously red, swollen, or tender of the superficial scalp.

Imaging studies {#Sec5}
---------------

Cranial CT scan showed an mixed iso-/hyperdensity mass in the right frontal cranial bone, about 60 to 198 Hu, measuring 34 × 21 mm, with clear margin. The peripheral bone appeared destructive absorption. The MR was contraindicated for metal implant (Figure [1](#Fig1){ref-type="fig"}).Figure 1Preoperative CT scan of the patient. The lesion locates in the right frontal bone, isointense on CT scan, with prominent bone destruction. **(a)** CT scan of the soft tissue. **(b)** CT scan of the cranial bone.

Surgery, pathologic result, and postoperative course {#Sec6}
----------------------------------------------------

The patient underwent total tumor resection through right frontal approach on 24 December, 2013. The tumor eroded both the external and internal lamina of the cranial bone. The tumor was solid, soft, tender, pale white, rich blood supplied, and was adhesive to the underlying dura mater. The dura mater was yet intact, sparing the parenchyma of the cortex. The intraoperative rapid frost pathologic examination revealed malignant changes, and so after tumor resection, the adjacent dura mater was removed as well which was reconstructed with self aponeurosis. The peripheral bone was resected to the negative zone. The excision margin was about 2 cm.

The pathologic examination reported amelanotic melanoma of intermediate grade, with positive of HMB45, MelanA (sparsely), S-100, Vimentin, CD99, SMA (sparsely), and CD34, and negative of CK, EMA, CEA, CK5/6, CK8/18, TTF-1, SYN, CD56, CgA, Desmin, MyoD1, TFE3, PAS, and PR. The Ki-67 was 20% to 30% (±) (Figure [2](#Fig2){ref-type="fig"}).Figure 2Pathologic results. **(a)** Pathology slice (hematoxylin-eosin stain, original magnification ×100) of the tumor. Nests of intermediate-grade tumor cells with intervening stroma can be seen. The tumor cells show clear to eosinophilic cytoplasm, with no obvious pigment. **(b)** Higher magnification (hematoxylin-eosin stain, original magnification ×400) of the tumor, showing prominent nuclear mitosis and atypia. **(c)** Higher magnification (original magnification ×400) of the tumor, showing HMB45 positive. **(d)** Higher magnification (original magnification ×400) of the tumor, showing S-100 positive. **(e)** Higher magnification (original magnification ×400) of the tumor, showing Vimentin-positive. **(f)** Higher magnification (original magnification ×400) of the tumor, showing Ki-67 index, was 20% to 30%.

The further examination includes CT scan of the chest, abdominal, and the pelvic region and the PET scan of the whole brain and body, which were all negative.

The patient was discharged 3 days after the operation with no complications and went on for adjuvant radiotherapy and chemotherapy (concomitant stereotactic radiosurgery + ipilimumab). For more than 5 months of follow-up, the patient recovers well with no recurrence or related sequelae.

Review of cases and literature {#Sec7}
------------------------------

We summarized the CNS melanocytic lesions of our neurosurgery department since 2008. Then we used the search engine of PubMed with keywords of melanoma or melanomatosis or melanocytoma or melanocytosis, and CNS and primary and further searched with keywords of CNS or brain or cranial or spinal, and amelanotic.

Thirty-two cases of CNS melanocytic lesions of our department were defined since 2008. Forty-three English reports of CNS melanocytic lesions and 14 reports about CNS amelanotic melanoma were searched. The details were summarized in the tables (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"}).Table 1**Summary of CNS melanocytic lesions of our neurosurgery department since 2008CaseGenderAge (yr.)LocationPathology diagnosisPreoperative differentiation** ^**a**^1M46Left temporalIntermediate-grade melanocytic tumor-2M11Right temporalMalignant melanoma-3M45Right frontalMalignant melanomaMetastasis? Lymphoma?4F26Right parasellarMalignant melanomaSchwannoma?5F52Left frontalMetastatic melanoma-6M43Right temporalMeningeal melanomatosisMetastasis? Pleomorphic xanthoastrocytoma?7M47Right CPAMeningeal melanomatosisEpidermoid cyst? Cavernous hemangioma?8M24Right lateral ventricleAmelanotic melanoma?-9F19Left parietalMelanocytomaMeningioma?10F21Right frontal, para-falxRecurrent melanocytoma, with subarachnoid disseminationRecurrent melanocytoma11M38Right petrosalMeningeal melanomatosisSchwannoma?12M61MultipleMelanocytoma with meningeal melanomatosisMelanoma? Metastasis?13M20Left temporalMalignant melanoma-14M24Right cerebellarMalignant melanomaCyst?15M47Foreman magnumMalignant melanoma, with bone invasionMeningioma? Melanoma?16M47Left middle fossaMalignant melanomaHemangiopericytoma? Meningioma? Melanoma?17M45Intradural extramedullary, C2-T1MelanocytomaMelanoma? Meningioma?18M31Right cavernous sinusMelanocytomaMelanoma? Cavernous hemangioma? Aneurysm?19M46Right middle fossaMalignant melanoma, with bone and dura invasionMeningioma?20M20Left ponsMalignant melanomaGlioma? Meningioma?21F41Multiple, T6-L1MelanocytomaNeurofibrosis?22F28Right parietal occipitalMalignant melanoma, with subarachnoid dissemination-23F66Left frontalMalignant melanoma-24M27Right interspinous foramen, C6MelanocytomaMelanoma?25M39Foramen magnum - C2MelanocytomaLipoma?26M36Right frontalMelanocytoma, with subarachnoid dissemination and parenchyma invasionMelanoma? Lymphoma?27M49Right cerebellar tentoriumMeningeal melanomatosisMeningioma?28M17Left parasallar - CPAMelanocytomaEpidermoid cyst?29M26MedullaIntermediate grade melanocytic tumor-30M13Right cerebellar tentoriumMalignant melanomaMeningioma? Hemangiopericytoma?31M47Left temporalMalignant melanoma-32M64Right frontal boneAmelanotic melanoma, with bone invasionEosinophilic granuloma? Giant cell osteoma? Metastasis?M, male; F, female, yr., years old. ^a^With no clear preoperative diagnosis.Table 2**Review of the English literature of CNS melanocytic lesionsAuthorYearNbPrimary/metastatic** ^**a**^**DiagnosisOther**Foit *et al*.20131PrimaryMelanocytoma-Lee *et al*.20131PrimaryMeningeal melanomatosis-Schneider *et al*.20131PrimaryMalignant melanoma-Reddy *et al*.20121-Melanocytoma-Sutton *et al*.20111-Leptomeningeal melanocytosisThe patient was suspected to represent a case of former fruste neurocutaneous melanosis.Brunsvig *et al*.1-Meningeal melanocytosis-Vij *et al*.20101PrimaryMelanoma-Perrini *et al*.20101PrimaryMalignant melanoma-Zadro *et al*.20101PrimaryDiffuse meningeal melanomatosis-Nishihara *et al*.20091PrimaryMalignant melanoma-Navas *et al*.20091-Meningeal melanocytomaAssociated with a congenital nevus of OtaHolfort *et al*.200916MetastaticMelanomaOut of review of primary uveal melanoma 2365 patientsMathai *et al*.20081-Intermediate grade meningeal melanocytoma-Tandon *et al*.20081PrimaryMelanocytoma-Levidou *et al*.20072Unknown primary siteLeptomeningeal melanoma-Cajaiba *et al*.20082PrimaryNeurocutaneous melanosis with CNS melanocytomaDisseminated to the peritoneal surface by ventriculo-peritoneal (V-P) shunt systemMekni *et al*.20075PrimaryMalignant melanoma-Denaro *et al*.20071PrimaryMelanoma-Bookland *et al*.20071PrimaryMalignant melanoma-Kiecker *et al*.20071PrimaryNeurocutaneous melanosis with meningeal melanoma-Oluigbo *et al*.20061PrimaryMalignant melanoma-Chen20031-Meningeal melanocytoma-Classen *et al*.20021-Melanocytoma-Rivers *et al*.20011PrimaryDural melanomaIn association with ocular melanosis and multiple cutaneous blue neviGreco Crasto *et al*.20011PrimaryMelanoma-Whinney *et al*.20011PrimaryMalignant melanoma-Kobayashi *et al*.20011-Malignant melanoma-Fathallah-Shaykh *et al*.19961PrimaryLeptomeningeal melanoma-Eaves *et al*.19951PrimaryMelanoma without diffuse leptomeningeal involvementA variant of neurocutaneous melanosisRubino *et al*.19931PrimaryMelanoma-Drake *et al*.19938PrimaryMalignant melanoma of the leptomeninges-Singhal *et al*.19911PrimaryMelanoma-Fish *et al*.19901PrimaryMelanoma-Salisbury *et al*.19891PrimaryMalignant melanomaIn association with a giant congenital melanocytic naevus of 'bathing trunk' distributionMacfarlane *et al*.19891PrimaryMalignant melanoma of the dura mater-Iglesias-Rozas *et al*.19891-Disseminated melanomatosis of the CNS and other organs-Larson *et al*.19875PrimaryMelanoma-Tamura *et al*.19811PrimaryLeptomeningeal malignant melanomaOriginated from the basal aspect of the brain. The tumor showed not only spinal meningeal dissemination but also infiltration into the petrous bone and along the trigeminal nerve till it reached the submucosal tissue of epipharynx.Pasquier *et al*.19781primaryMelanomaWith multiple metastases in the liverHayward19762720 Metastatic, 6 PrimaryMalignant melanoma-Kaplan *et al*.19751PrimaryNeurocutaneous melanosis with malignant leptomeningeal melanoma-Enriquez *et al*.19731PrimaryMalignant melanomaPineal involvement in a patient with nevus of ota and multiple pigmented skin nevi.Bergdahl *et al*.197210PrimaryMalignant melanoma-CNS, central nervous system, the involved cases are all of the CNS, either intracranial or intraspinal; Nb, number of reported cases. ^a^Some cases have no clear evidence to be defined as primary or metastatic tumor.Table 3**Review of the literature of CNS amelanotic melanomaAuthorYearNbPrimary/metastatic** ^**a**^**DiagnosisOther** ^**b**^Schulz *et al*. \[[@CR6]\]20121PrimaryMalignant amelanotic melanomas(in German)Combined multiple intracranial and intraspinal primary malignant amelanotic melanomasCemil *et al*. \[[@CR7]\]20081MetastaticAmelanotic melanoma-Karakis *et al*. \[[@CR8]\]20071MetastaticAmelanotic melanoma-Jacob *et al*. \[[@CR9]\]20061-Amelanotic melanoma?-Li *et al*. \[[@CR10]\]20041-Amelanotic melanoma?(in Chinese)Ogawa *et al*. \[[@CR11]\]20031MetastaticAmelanotic melanoma-Shields *et al*. \[[@CR12]\]20021MetastaticAmelanotic melanoma-Isiklar *et al*. \[[@CR13]\]199516MetastaticAmelanotic melanoma-Schadendorf *et al*. \[[@CR14]\]19931-Amelanotic malignant melanoma-Takahashi *et al*. \[[@CR15]\]19901MetastaticAmelanotic melanoma(in Japanase)Krüger *et al*. \[[@CR16]\]19871MetastaticAmelanotic melanomaAssociated with a congenital nevus of OtaSunada *et al*. \[[@CR17]\]19861Unknown originAmelanotic melanoma(in Japanase)Out of review of primary uveal melanoma 2365 patientsWagner *et al*. \[[@CR18]\]19811-Amelanotic melanomaAmelanotic melanoma of the lung and brainSchuknecht *et al*. \[[@CR5]\]19902PrimaryMeningeal amelanotic malignant melanoma-CNS, central nervous system, the involved cases are all of the CNS, either intracranial or intraspinal; Nb, number of reported cases. ^a^Some cases have no clear evidence to be defined as primary or metastatic tumor; ^b^literature in languages other than English is noted.

Discussion {#Sec8}
==========

Primary melanocytic neoplasms of the CNS belong to the tumors of the meninges, further classified as diffuse melanocytosis, melanocytoma, malignant melanoma, and meningeal melanomatosis. The incidence is 0.06% to 0.1% of melanocytoma and 0.005/100,000 of melanoma. Other subtypes are rare. There is a slight female predisposition, with the ratio of F:M = 1.5:1. The age range of melanocytoma is 9 to 73 years, most frequently from 45 to 50 years, and of the primary nodular melanoma is 15 to 71 years, averaging 43 years. The symptoms and signs are secondary to either the local effects on the CNS parenchyma or the accompanying hydrocephalus. The rapid progress with increasing ICP resulting in irritability, vomiting, lethargy, seizures, and so on may suggest malignant transformation. The diagnosis of melanocytic lesions relies on the histopathological examination. Most benign and malignant melanocytic lesions display melanin pigment distributed within tumor cells, tumor stroma, and the cytoplasm of tumoral macrophages (melanophages). Tumor with CNS invasion or elevated mitotic activity is classified as intermediate grade melanocytic neoplasms. Malignant melanoma is more pleomorphic, has more anaplastic nuclei, higher cell density, and unequivocal invasion or coagulative necrosis. Rare melanocytomas and occasional primary melanomas will not demonstrate melanin pigment, complying with 'amelanotic' Amelanotic melanoma may arise from normal melanoma with amelanotic transformation or detergent of the tumor cell. Histopathological and immunohistochemistry examinations are highly sensitive to amelanotic melanoma. The neuroimaging performance depends on the content of melanin. Isiklar *et al*. \[[@CR1]\] classified the MR performance into four groups: a) The melanotic group, with hyperintense on T1 and hypointense on T2. b) The amelanotic group, with iso-/hypointense on T1 and iso-/hyperintense on T2. c) The mixed group, suiting neither the two criteria. d) The hemorrhagic group, with characteristics of intra-/peri-tumoral hemorrhage. Gaviani *et al*. \[[@CR2]\] reported that the T1 signal has positive correlation with the content of melanin, while T2 signal has no such correlation but is more sensitive to tiny loci.

Early in 1980s, Willis *et al*. pointed out that the diagnosis of 'primary' has to meet three critical conditions: a) The skin or eyeballs are negative of melanoma. b) The skin or eyeballs have no history of melanoma resection. c) The internal organs are negative of metastasis of melanoma. Savitz \[[@CR3]\] thought that the systemic melanocytic lesions are very likely to metastases to CNS while the primary loci are quite indolent. Winkelman *et al*. \[[@CR4]\] reported that 44% of all melanocytic lesions have CNS metastasis at autopsy, so that the 'primary' can only be confirmed after autopsy. So every melanocytic neoplasm may be a systemic disease, and the 'primary CNS melanocytic lesion' is just a subtype with CNS as the single manifestation clinically. There are approximately more than 60 papers describing primary CNS melanocytic lesions, with about 40 are in English, dated from 1972 to 2013. The number of cases ranged from one to ten. The symptoms are various according to the location of the tumor and so are the neuroimaging performance relating to the content of the melanin, as mentioned before. About 14 papers referred to CNS amelanotic melanoma, from 1981 to 2012. Most are case reports, including two primary intraspinal and two primary meningeal amelanotic melanoma, 22 intracerebral metastasis, one intraventricular metastasis, and three cases with no details. Schuknecht *et al*. \[[@CR5]\] reported two primary meningeal amelanotic melanoma in 1990, serving as the only paper describing primary CNS amelanotic melanoma. There are totally 32 primary or metastatic CNS melanocytic lesions of our department since 2008. The cases diagnosed earlier are not included because of the controversial diagnosis criterion before the 2007 WHO classification which are widely adopted. The location involves all the CNS, from supratentorial to intraspinal region. Due to the unspecific resemblance, there were only few cases which were diagnosed before surgery, and the differentiations were quite variable. The most common differentiations are tumors of the meninges, which belong to the same group of the melanocytic lesions, such as meningioma and the mesenchymal tumors. The hematopoietic neoplasms, cavernous hemangioma, and even the cystic lesions are also involved especially when there are hemorrhage, cystic changes, or necrosis, and so on. One of them was suspected as amelanotic melanoma. Our case is the second one with definite diagnosis of amelanotic melanoma. The clinical characteristics of amelanotic melanoma are similar to other melanocytic lesions, with the neuroimaging performance as the major difference. Also, during the operation, the amelanotic melanoma appears more pale white, and the microscopic examination reviews the lacking of melanin. As the overall examinations were all negative, the primary intracranial amelanotic melanoma was confirmed.

The prognosis of amelanotic melanoma is not quite different from other CNS melanoma. Melanocytoma lacks anaplastic features, but a few undergo local recurrences. Intermediate grade melanocytic tumors typically invade the CNS. A rare example of malignant transformation of a melanocytoma has been reported. Malignant melanoma is highly aggressive and radioresistant, has poor prognosis, and prone to metastasize. The prognosis of diffuse melanosis is poor even in the absence of histologic malignancy. The prognosis of the primary CNS melanocytic lesions appears to be better than metastatic examples. For our case of primary intracranial amelanotic melanoma, total resection was achieved as well as excessive removal of invaded cranial bone and adjacent meninges. The experience of postoperative adjuvant therapy is quite poor. We adopted the radiotherapy and chemotherapy regimen of concomitant stereotactic radiosurgery + ipilimumab, referring to the NCCN guidelines for melanoma (2.2015 version). With adjuvant radiotherapy and chemotherapy, the patient is tumor-free 5 months later and is still under follow-up.

Conclusions {#Sec9}
===========

CNS amelanotic melanoma is quite rare. The clinical characteristics are similar to other melanocytic lesions, with the neuroimaging performance as the major difference. The prognosis of amelanotic melanoma is not quite different from other CNS melanoma and appears to be better than the metastatic cases, particularly if localized and complete resection is possible.

Consent {#Sec10}
=======

Written informed consent was obtained from the patient for the publication of this case presentation and accompanying images. A copy of the written consent is available for the review by the Editor of this journal.
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